Trial reportTranslational psychiatry2019
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
Trial report in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- The effect of SSRIs on Semen quality: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- ERICH3: vesicular association and antidepressant treatment response.Molecular psychiatry · 2021Pooled it
- Metabolome Profiling of Yokukansan in Preventing Postoperative Delirium in Elderly Cancer Patients: A Reverse Translational Study.Psychiatry and clinical neurosciences · 2025Trial
- The effect of SSRI/SNRI antidepressant treatment on the gut microbiota of patients with major depressive disorder.Communications medicine · 2026Article
- Comparison of fecal and plasma metabolite correlations following nutrition or exercise interventions.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Metabolomic and gut microbial biomarkers of smoking cessation treatment in long-term drug therapy: a study protocol for a randomized controlled trial.Frontiers in psychiatry · 2026Article
- Application of Treatment Response Biomarkers from Major Depression to Perinatal Depression.Journal of personalized medicine · 2025Review
- Paroxetine Triggers Inflammatory State on Zebrafish Early Embryonic Development.Life (Basel, Switzerland) · 2025Article
- Longitudinal metabolic profiling of women using selective serotonin reuptake inhibitors during pregnancy.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Restoring Balance: Probiotic Modulation of Microbiota, Metabolism, and Inflammation in SSRI-Induced Dysbiosis Using the SHIMEPharmaceuticals (Basel, Switzerland) · 2025Article
- Medication use is associated with distinct microbial features in anxiety and depression.Molecular psychiatry · 2025Article
- The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.CNS neuroscience & therapeutics · 2025Article
- Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications.Current obesity reports · 2025Review
- Article
- HMGB1/STAT3/p65 axis drives microglial activation and autophagy exert a crucial role in chronic Stress-Induced major depressive disorder.Journal of advanced research · 2024Article
- Effect of gut microbiome on serotonin metabolism: a personalized treatment approach.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Metabolomics Signatures of serotonin reuptake inhibitor (Escitalopram), serotonin norepinephrine reuptake inhibitor (Duloxetine) and Cognitive Behavior Therapy on Key Neurotransmitter Pathways in Major Depressive Disorder.medRxiv : the preprint server for health sciences · 2024Article
- Medication Use is Associated with Distinct Microbial Features in Anxiety and Depression.bioRxiv : the preprint server for biology · 2024Article
- Mind, Mood and Microbiota-Gut-Brain Axis in Psychiatric Disorders.International journal of molecular sciences · 2024Review
- Finding the best predictive model for hypertensive depression in older adults based on machine learning and metabolomics research.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Funding
Abstract
Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.